Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of JNJ-75105186 in Healthy Japanese and Chinese Participants
NCT05159128Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Apr 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PN-232 in inflammatory bowel disease (IBD) and psoriasis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety and Tolerability up to 6 weeks and Plasma Concentration of JNJ-75105186. Planned start Nov 2021; status: withdrawn.
02
Drugs
PN-232
03
Conditions
inflammatory bowel disease (IBD)psoriasis
Beyond the preview
Go deeper on NCT05159128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159128.